IL-35 Is Involved in the Pathogenesis of Guillain–Barré Syndrome Through Its Influence on the Function of CD4+ T Cells

References

• Adamson AS, Collins K, Laurence A, O'Shea JJ. (2009). The current STATs of lymphocyte signaling: New roles for old players. Curr Opin Immunol, 21, 161–6
   PubMed Web of Science ®Google Scholar
• Agnello D, Lankford CS, Bream J, et al. (2003). Cytokines and transcription factors that regulate T helper cell differentiation: New players and new insights. J Clin Immunol, 23, 147–61
   PubMed Web of Science ®Google Scholar
• Borsellino G, Koul O, Placido R, et al. (2000). Evidence for a role of gammadelta T cells in demyelinating diseases as determined by activation states and responses to lipid antigens. J Neuroimmunol, 24, 124–9
   Web of Science ®Google Scholar
• Burchill MA, Yang J, Vang KB, et al. (2008). Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire. Immunity, 28, 112–21
   PubMedGoogle Scholar
• Burchill MA, Yang J, Vogtenhuber C, et al. (2007). IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol, 178, 280–90
   PubMed Web of Science ®Google Scholar
• Castellani ML, Anogeianaki A, Felaco P, et al. (2010). IL-35, an anti-inflammatory cytokine which expands CD4+CD25+ Treg Cells. J Biol Regul Homeost Agents, 24, 131–5
   PubMed Web of Science ®Google Scholar
• Chabaud M, Fossiez F, Taupin JL, Miossec P. (1998). Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokine. J Immunol, 161, 409–14
   PubMed Web of Science ®Google Scholar
• Collison LW, Chaturvedi V, Henderson AL, et al. (2010). IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol, 11, 1093–7
   PubMed Web of Science ®Google Scholar
• Collison LW, Delgoffe GM, Guy CS, et al. (2007b). Reduced circulating CD4+ CD25+ cells in Guillain-Barré syndrome. J Neuroimmunol, 183, 232–8
   PubMed Web of Science ®Google Scholar
• Collison LW, Delgoffe GM, Guy CS, et al. (2012). The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol, 13, 290–9
   PubMed Web of Science ®Google Scholar
• Collison LW, Pillai MR, Chaturvedi V, Vignali DA. (2009). Regulatory T cells uppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol, 182, 6121–8
   PubMed Web of Science ®Google Scholar
• Collison LW, Vignali DA. (2008). Interleukin-35: Odd one out or part of the family. Immunol Rev, 226, 248–62
   PubMed Web of Science ®Google Scholar
• Collison LW, Workman CJ, Kuo TT, et al. (2007a). The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature, 450, 566–9
   PubMed Web of Science ®Google Scholar
• Deng H, Yang X, Jin T, et al. (2008). The role of IL-12 and TNF-alpha in AIDP and AMAN. Eur J Neurol, 5, 1100–5
   Web of Science ®Google Scholar
• Feng BS, Zheng PY, Chen X, et al. (2008). Investigation of the role of cholera toxin in assisting the initiation of the antigen-specific Th2 response. Immunol Invest, 37, 782–97
   PubMed Web of Science ®Google Scholar
• Girkontaite I, Urbonaviciute V, Maseda D, et al. (2007). Apoptotic cells selectively suppress the Th1 cytokine interferon gamma in stimulated human peripheral blood mononuclear cells and shift the Th1/Th2 balance towards Th2. Autoimmunity, 40, 327–30
   PubMed Web of Science ®Google Scholar
• Hartung HP, Zielasek J, Jung S, Toyka KV. (1996). The role of cytokines in Guillain–Barr syndrome. Rev Neurol, 152, 320–7
   PubMedGoogle Scholar
• Heltemes-Harris LM, Willette MJ, Vang KB, Farrar MA. (2011). The role of STAT5 in the development, function, and transformation of B and T lymphocytes. Ann NY Acad Sci, 1217, 18–31
   PubMed Web of Science ®Google Scholar
• Hohnoki K, Inoue A, Koh CS. (1998). Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. J Neuroimmunol, 87, 27–32
   PubMed Web of Science ®Google Scholar
• Jacobson NG, Szabo SJ, Weber-Nordt RM, et al. (1995). Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat) 3 and Stat4. J Exp Med, 181, 1755–62
   PubMed Web of Science ®Google Scholar
• Kelchtermans H, Schurgers E, Geboes L, et al. (2009). Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-gamma and counteraction by interferon-gamma. Arthritis Res Ther, 11, R122
   PubMed Web of Science ®Google Scholar
• Kidd P. (2003). Th1/Th2 balance: The hypothesis, its limitations, and implications for health and disease. Altern Med Rev, 8, 223–46
   PubMedGoogle Scholar
• Laurence A, Tato CM, Davidson TS, et al. (2007). Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity, 26, 371–81
   PubMed Web of Science ®Google Scholar
• Luger D, Silver PB, Tang J, et al. (2008). Either a Th17 or a Th1 effector response can drive autoimmunity: Conditions of disease induction affect dominant effector category. J Exp Med, 205, 799–810
   PubMed Web of Science ®Google Scholar
• Muthian G, Raikwar HP, Johnson C, et al. (2006). COX-2 inhibitors modulate IL-12 signaling through JAK-STAT pathway leading to Th1 response in experimental allergic encephalomyelitis. J Clin Immunol, 26, 73–85
   PubMed Web of Science ®Google Scholar
• Niedbala W, Wei XQ, Cai B, et al. (2007). IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol, 37, 3021–9
   PubMed Web of Science ®Google Scholar
• Nyati KK, Prasad KN, Rizwan A, et al. (2011). Th1 and Th2 response to Campylobacter jejuni antigen in Guillain-Barre syndrome. Arch Neurol, 68, 445–52
   PubMed Web of Science ®Google Scholar
• Press R, Ozenci V, Kouwenhoven M, Link H. (2002). Non-T(H)1 cytokines are augmented systematically early in Guillain-Barre syndrome [J]. Neurology, 58, 476–8
   PubMed Web of Science ®Google Scholar
• Schmidt-Weber CB, Alexander SI, Henault LE, et al. (1999). IL-4 enhances IL-10 gene expression in murine Th2 cells in the absence of TCR engagement. J Immunol, 162, 238–44
   PubMed Web of Science ®Google Scholar
• Sezavar H, Saboor-Yaraghi AA, Salehi E, Mottaghi A. (2015). Whether vitamin A supplementation is effective in T-bet and IFN-γ gene expression reduction? Immunol Invest, 44, 189–98
   PubMed Web of Science ®Google Scholar
• Sinigaglia F, D'Ambrosio D, Rogge L. (1999). Type I interferons and the Th1/Th2 paradigm. Dev Comp Immunol, 23, 657–63
   PubMed Web of Science ®Google Scholar
• Sredni-Kenigsbuch D. (2002). TH1/TH2 cytokines in the central nervous system. Int J Neurosci, 112, 665–703
   PubMed Web of Science ®Google Scholar
• Su SB, Grajewski RS, Luger D, et al. (2007). Altered chemokine profile associated with exacerbated autoimmune pathology under conditions of genetic interferon-gamma deficiency. Invest Ophthalmol Vis Sci, 48, 4616–25
   PubMed Web of Science ®Google Scholar
• Tatsumoto M, Koga M, Gilbert M, et al. (2006). Spectrum of neurological diseases associated with antibodies to minor gangliosides GM1b and GalNAc-GDla. J Neuroimmunol, 177, 201–8
   PubMed Web of Science ®Google Scholar
• Van Doorn PA, Ruts L, Jacobs BC. (2008). Clinical features, pathogenesis, and treatment of Guillain–Barre syndrome. Lancet Neurol, 7, 939–50
   PubMed Web of Science ®Google Scholar
• Villarino AV, Gallo E, Abbas AK. (2010). STAT1-activating cytokines limit Th17 responses through both T-bet-dependent and -independent mechanisms. J Immunol, 185, 6461–71
   PubMed Web of Science ®Google Scholar
• Wang M, Yang L, Sheng X, et al. (2011). T-cell vaccination leads to suppression of intrapancreatic Th17 cells through Stat3-mediated RORγt inhibition in autoimmune diabetes. Cell Res, 21, 1358–69
   PubMed Web of Science ®Google Scholar
• Yao Z, Kanno Y, Kerenyi M, et al. (2007). Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood, 109, 4368–75
   PubMed Web of Science ®Google Scholar
• Zhang HL, Li HF. (2011). The TH1/TH2 paradigm in Guillain–Barre syndrome. Arch Neurol, 68, 1209–10
   PubMed Web of Science ®Google Scholar
• Zhang HL, Zheng XY, Zhu J. (2013). Th1/Th2/Th17/Treg cytokines in Guillain–Barré syndrome and experimental autoimmune neuritis. Cytokine Growth Factor Rev, 24, 443–53
   PubMed Web of Science ®Google Scholar